Efficacy and Safety of Alogliptin Plus Metformin in Patients With Type 2 Diabetes (AM7D)

A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Determine the Efficacy and Safety of Alogliptin Plus Metformin, Alogliptin Alone, or Metformin Alone in Subjects With Type 2 Diabetes

The purpose of this study is to evaluate the safety and effectiveness of alogliptin combined with metformin, once daily (QD) or twice daily (BID), in participants with Type 2 Diabetes.

Study Overview

• Status: Completed
• Conditions: Diabetes Mellitus, Type 2
• Intervention / Treatment: Drug: Alogliptin; Drug: Alogliptin Placebo; Drug: Metformin Placebo; Drug: Metformin

Detailed Description

There are approximately 19 million people in the United States who have been diagnosed with diabetes mellitus, of which 90% to 95% are type 2. The prevalence of type 2 diabetes varies among racial and ethnic populations and has been shown to correlate with age, obesity, family history, history of gestational diabetes and physical inactivity. Over the next decade, a marked increase in the number of adults with diabetes mellitus is expected.

Metformin is the usual choice of first-line therapy for type 2 diabetes. Metformin targets insulin resistance in type 2 diabetes by inhibiting hepatic glucose production and stimulating glucose uptake in skeletal muscle and adipose tissue, which results in a long-term glucose-lowering effect.

Alogliptin is an inhibitor of the dipeptidyl peptidase IV enzyme. Dipeptidyl peptidase-4 enzyme is thought to be primarily responsible for the in vivo degradation of 2 peptide hormones released in response to nutrient ingestion, namely glucagon-like peptide-1 and glucose-dependent insulinotropic peptide. Both peptides exert important effects on islet beta cells to stimulate glucose-dependent insulin secretion as well as regulating beta cell proliferation and cytoprotection. Glucagon-like peptide-1, but not glucose-dependent insulinotropic peptide, inhibits gastric emptying, glucagon secretion, and food intake. Glucose-dependent insulinotropic peptide has been shown to enhance insulin secretion by direct interaction with a glucose-dependent insulinotropic peptide -specific receptor on islet beta cells. The glucose-lowering actions of glucagon-like peptide-1, but not glucose-dependent insulinotropic peptide, are preserved in patients with type 2 diabetes mellitus. It is expected that inhibition of dipeptidyl peptidase IV will improve glycemic (glucose) control in patients with type 2 diabetes.

Based on the potential, complimentary mechanisms of action of alogliptin and metformin, this study will compare the safety and efficacy of alogliptin and metformin (SYR-322MET) on improving glycemic control in patients with type 2 diabetes mellitus who are inadequately controlled by diet adjustment and exercise alone.

Participants taking part in this study will receive dietary and exercise coaching, and will monitor their own blood glucose concentrations with a home glucose monitor. Participants will also be required to maintain a hypoglycemic diary throughout the course of the study. Participation in this study is expected to last up to 34 weeks.

• Study Type: Interventional
• Enrollment (Actual): 784
• Phase: Phase 3

Contacts and Locations

Study Locations

• Czech Republic
  • Hradec Kralove, Czech Republic
  • Olomouc, Czech Republic
  • Ostrava, Czech Republic
  • Praha 10, Czech Republic
  • Zlin, Czech Republic
  • Znojmo, Czech Republic
• Hungary
  • Budaors, Hungary
  • Debrecen, Hungary
  • Gyongyos, Hungary
  • Gyor, Hungary
  • Gyula, Hungary
  • Komarom, Hungary
  • Szolnok, Hungary
  • Zalaegerszeg, Hungary
• Israel
  • Haifa, Israel
  • Holon, Israel
  • Kfar Saba, Israel
  • Nahariya, Israel
  • Safed, Israel
• Lithuania
  • Kaunas, Lithuania
  • Kedainiai, Lithuania
  • Klaipeda, Lithuania
  • Vilnius, Lithuania
• Mexico
  • Acapulco, Guerrero, Mexico
  • Cuernavaca, Mexico
  • Culiacan, Sinoloa, Mexico
  • Distrito Federal, Mexico
  • Durango, Mexico
  • Durango, Durango, Mexico
  • Guadalajara, Mexico
  • Mexico City, Mexico
  • Mexico City, Mexico, Mexico
  • Mexico, DF, Mexico
  • Monclova, Coahuila, Mexico
  • Monterrey, Mexico
  • Monterrey, NL, Mexico
  • Pachuca, Mexico
  • Pachuca, Hidalgo, Mexico
  • Saltillo, Mexico
  • Tijuana, Baja California, Mexico
  • Zapopan, Jalisco, Mexico
• Poland
  • Bialystok, Poland
  • Bytom, Poland
  • Gniewkowo, Poland
  • Grodzisk Mazowiecki, Poland
  • Kamieniec Zabkowicki, Poland
  • Leczyca, Poland
  • Warszawa, Poland
  • Wroclaw, Poland
• Puerto Rico
  • Caguas, Puerto Rico
  • Cidra, Puerto Rico
  • Ponce, Puerto Rico
  • Salinas, Puerto Rico
  • San Juan, Puerto Rico
  • Santurce, Puerto Rico
  • Trujilo Alto, Puerto Rico
• Romania
  • Bacau, Romania
  • Baia Mare, Romania
  • Bucharest, Romania
  • Constanta, Romania
  • Iasi, Romania
  • Ploiesti, Romania
• Russian Federation
  • Arkhangelsk, Russian Federation
  • Irkutsk, Russian Federation
  • Kemerovo, Russian Federation
  • Moscow, Russian Federation
  • Perm, Russian Federation
  • St. Petersburg, Russian Federation
  • Ufa, Russian Federation
• Slovakia
  • Banska Bystrica, Slovakia
  • Kosice, Slovakia
  • Lucenec, Slovakia
  • Nitra, Slovakia
  • Presov, Slovakia
  • Prievidza, Slovakia
  • Sahy, Slovakia
  • Zilina, Slovakia
• South Africa
  • Pretoria, South Africa
  • Gauteng
    • Centurion, Gauteng, South Africa
    • Johannesburg, Gauteng, South Africa
    • Pretoria, Gauteng, South Africa
  • Kwazulu-Natal
    • Durban, Kwazulu-Natal, South Africa
  • Western Cape
    • Cape Town, Western Cape, South Africa
• Ukraine
  • Dnipropetrovsk, Ukraine
  • Donetsk, Ukraine
  • Ivano-Frankivsk, Ukraine
  • Kharkiv, Ukraine
  • Kyiv, Ukraine
  • Lviv, Ukraine
  • Odesa, Ukraine
  • Vinnytsya, Ukraine
  • Zaporizhzhya, Ukraine
• United States
  • Alabama
    • Dothan, Alabama, United States
    • Muscle Shoals, Alabama, United States
    • Pell City, Alabama, United States
  • Arizona
    • Chandler, Arizona, United States
    • Mesa, Arizona, United States
    • Phoenix, Arizona, United States
    • Sierra Vista, Arizona, United States
    • Tempe, Arizona, United States
  • Arkansas
    • Little Rock, Arkansas, United States
    • Searcy, Arkansas, United States
    • Tempe, Arkansas, United States
  • California
    • Anaheim, California, United States
    • Buena Park, California, United States
    • Cathedral City, California, United States
    • National City, California, United States
    • Pismo Beach, California, United States
    • Roseville, California, United States
    • Santa Ana, California, United States
  • Colorado
    • Colorado Springs, Colorado, United States
  • Florida
    • Boca Raton, Florida, United States
    • Bradenton, Florida, United States
    • Cutler Bay, Florida, United States
    • Hialeah, Florida, United States
    • Lauderdale Lakes, Florida, United States
    • Miami, Florida, United States
    • Ocala, Florida, United States
    • Opa Locka, Florida, United States
    • Orlando, Florida, United States
    • Panama City, Florida, United States
    • Pembroke Pines, Florida, United States
  • Georgia
    • Atlanta, Georgia, United States
    • Blue Ridge, Georgia, United States
    • Decatur, Georgia, United States
    • Lawrenceville, Georgia, United States
  • Idaho
    • Hayden Lake, Idaho, United States
  • Illinois
    • Chicago, Illinois, United States
    • Melrose Park, Illinois, United States
  • Indiana
    • La Porte, Indiana, United States
    • Mishawaka, Indiana, United States
  • Iowa
    • Council Bluffs, Iowa, United States
    • Dubuque, Iowa, United States
  • Kansas
    • Topeka, Kansas, United States
  • Kentucky
    • Lexington, Kentucky, United States
    • Louisville, Kentucky, United States
  • Louisiana
    • Marrero, Louisiana, United States
  • Maryland
    • Oxon Hill, Maryland, United States
  • Massachusetts
    • North Dartmouth, Massachusetts, United States
  • Michigan
    • Dearborn, Michigan, United States
    • Flint, Michigan, United States
    • Kalamazoo, Michigan, United States
  • Mississippi
    • Picayune, Mississippi, United States
  • Missouri
    • St. Louis, Missouri, United States
  • Nebraska
    • Omaha, Nebraska, United States
  • Nevada
    • Henderson, Nevada, United States
    • Las Vegas, Nevada, United States
  • New Jersey
    • Brick, New Jersey, United States
    • Elizabeth, New Jersey, United States
  • New York
    • North Massapequa, New York, United States
  • North Carolina
    • Asheville, North Carolina, United States
    • Charlotte, North Carolina, United States
    • Greensboro, North Carolina, United States
    • Mooresville, North Carolina, United States
  • North Dakota
    • Fargo, North Dakota, United States
  • Ohio
    • Cincinnati, Ohio, United States
    • Cleveland, Ohio, United States
    • Gallipolis, Ohio, United States
    • Mason, Ohio, United States
    • Maumee, Ohio, United States
  • Oklahoma
    • Norman, Oklahoma, United States
    • Oklahoma City, Oklahoma, United States
    • Tulsa, Oklahoma, United States
  • Pennsylvania
    • Altoona, Pennsylvania, United States
    • Bensalem, Pennsylvania, United States
    • Downingtown, Pennsylvania, United States
    • Fleetwood, Pennsylvania, United States
    • Perkasie, Pennsylvania, United States
    • Shippensburg, Pennsylvania, United States
    • Tipton, Pennsylvania, United States
    • Uniontown, Pennsylvania, United States
  • South Carolina
    • Columbia, South Carolina, United States
    • Greenville, South Carolina, United States
    • Murrells Inlet, South Carolina, United States
    • North Myrtle Beach, South Carolina, United States
    • Taylors, South Carolina, United States
  • Tennessee
    • Brentwood, Tennessee, United States
    • Bristol, Tennessee, United States
    • Crossville, Tennessee, United States
    • Johnson City, Tennessee, United States
    • McKenzie, Tennessee, United States
    • Spring Hill, Tennessee, United States
  • Texas
    • Carrollton, Texas, United States
    • Dallas, Texas, United States
    • Deer Park, Texas, United States
    • El Paso, Texas, United States
    • Houston, Texas, United States
    • Hurst, Texas, United States
    • Katy, Texas, United States
    • Odessa, Texas, United States
    • San Antonio, Texas, United States
    • Schertz, Texas, United States
    • Spring, Texas, United States
    • Sugarland, Texas, United States
    • Temple, Texas, United States
  • Utah
    • Bountiful, Utah, United States
    • Ogden, Utah, United States
    • Salt Lake City, Utah, United States
  • Vermont
    • South Burlington, Vermont, United States
  • Virginia
    • Petersburg, Virginia, United States
  • Wisconsin
    • Milwaukee, Wisconsin, United States

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 18 years to 80 years (Adult, Older Adult)
• Accepts Healthy Volunteers: No
• Genders Eligible for Study: All

Description

Inclusion Criteria:

• Has historical diagnosis of Type 2 Diabetes Mellitus.
• Has been treated with diet and exercise for at least 2 months prior to Screening, and has a Glycosylated Hemoglobin concentration between 7.5% and 10.0%, inclusive at Screening.
• Has received less than 7 days of any antidiabetic medication within 2 months prior to Screening.
• Body mass index greater than or equal to 23 kg/m^2 and less than or equal to 45 kg/m^2 (except for Asian or Asian-descendant subjects for whom the range is between 20 and 35 kg/ m^2, inclusive).
• Fasting C-peptide concentration greater than or equal to 0.8 ng/mL.
• Regularly using other, non-excluded, medications must be on a stable dose for at least the 4 weeks prior to Screening.
• Females of childbearing potential and males who are sexually active agree to routinely use adequate contraception from Screening throughout the duration of the study.
• Able and willing to monitor their own blood glucose concentrations with a home glucose monitor and complete patient diaries.

Exclusion Criteria:

• Hemoglobin less than 12 g/dL for males and less than 10 g/dL for females at Screening Visit.
• Has a history of any hemoglobinopathy that may affect determination of Glycosylated Hemoglobin.
• Has a history of laser treatment for proliferative diabetic retinopathy within the 6 months prior to Screening.
• Has a history of treatment for diabetic gastric paresis, gastric banding, or gastric bypass surgery.
• Has a history of diabetic ketoacidosis or hyperosmolar non-ketotic coma.
• Has systolic blood pressure greater than or equal to 150 mmHg and /or diastolic pressure greater than or equal to 90 mmHg at Screening visit.
• Has New York Heart Association Class III to IV heart failure.
• Has a history of coronary angioplasty, coronary stent placement, coronary bypass surgery, or myocardial infarction within the 90 days prior to Screening.
• Has Alanine aminotransferase greater than 3 times the upper limit of normal at Screening.
• Has a history of alcohol or substance abuse with the 2 years prior to Screening.
• Serum creatinine greater than or equal to 1.5 mg/dL for males and greater than or equal to 1.4 mg/dL for females.
• Has history of cancer, other than squamous cell or basal cell carcinoma of the skin that has not been in full remission for at least 5 years prior to Screening.
• Has a history of infection with human immunodeficiency virus, hepatitis B virus or hepatitis C virus.
• Has any major illness or debility that in the investigator's opinion prohibits the subject from completing the study.
• Has received any investigational drug within the 90 days prior to Screening.
• Has a history of hypersensitivity or allergy to alogliptin, other DPP-4 inhibitors, metformin or related compounds.
• Has used oral or systematically injected glucocorticoids or weight loss drugs prior to 2 months to screening.

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Treatment
• Allocation: Randomized
• Interventional Model: Parallel Assignment
• Masking: Quadruple

Number of Arms

7

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Placebo Comparator: Placebo; Alogliptin placebo-matching tablets, orally, twice daily and Metformin placebo-matching capsules, orally, twice daily for up to 26 weeks.	Drug: Alogliptin Placebo; Alogliptin placebo-matching tablets.; Drug: Metformin Placebo; Metformin placebo-matching capsules.
Experimental: Alogliptin 25 QD; Alogliptin 25 mg, tablets, orally, once daily (QD) and Metformin placebo-matching capsules, orally, twice daily for up to 26 weeks.	Drug: Alogliptin; Alogliptin tablets.; Other Names: SYR-322; Drug: Metformin Placebo; Metformin placebo-matching capsules.
Experimental: Alogliptin 12.5 BID; Alogliptin 12.5 mg, tablets, orally, twice daily (BID) and Metformin placebo-matching capsules, orally, twice daily for up to 26 weeks.	Drug: Alogliptin; Alogliptin tablets.; Other Names: SYR-322; Drug: Metformin Placebo; Metformin placebo-matching capsules.
Active Comparator: Metformin 500 BID; Alogliptin placebo-matching tablets, orally, twice daily and Metformin 500 mg capsules, orally, twice daily for up to 26 weeks.	Drug: Alogliptin Placebo; Alogliptin placebo-matching tablets.; Drug: Metformin; Metformin capsules; Other Names: Glucophage; Glucophage XR; Glumetza; Fortamet; Riomet; Diabex; Dianben; Obimet; Diaformin
Active Comparator: Metformin 1000 BID; Alogliptin placebo-matching tablets, orally, twice daily and Metformin 1000 mg capsules, orally, twice daily for up to 26 weeks.	Drug: Alogliptin Placebo; Alogliptin placebo-matching tablets.; Drug: Metformin; Metformin capsules; Other Names: Glucophage; Glucophage XR; Glumetza; Fortamet; Riomet; Diabex; Dianben; Obimet; Diaformin
Experimental: Alogliptin 12.5 BID + Metformin 500 BID; Alogliptin 12.5mg, tablets, orally, twice daily and Metformin 500 mg, capsules, orally, twice daily for up to 26 weeks.	Drug: Alogliptin; Alogliptin tablets.; Other Names: SYR-322; Drug: Metformin; Metformin capsules; Other Names: Glucophage; Glucophage XR; Glumetza; Fortamet; Riomet; Diabex; Dianben; Obimet; Diaformin
Experimental: Alogliptin 12.5 BID + Metformin 1000 BID; Alogliptin 12.5 mg, tablets, orally, twice daily and Metformin 1000 mg, capsules, orally, twice daily for up to 26 weeks.	Drug: Alogliptin; Alogliptin tablets.; Other Names: SYR-322; Drug: Metformin; Metformin capsules; Other Names: Glucophage; Glucophage XR; Glumetza; Fortamet; Riomet; Diabex; Dianben; Obimet; Diaformin

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Change From Baseline in Glycosylated Hemoglobin (HbA1c) at Week 26	The change from Baseline to Week 26 in HbA1c (the concentration of glucose bound to hemoglobin as a percent of the absolute maximum that can be bound).	Baseline and Week 26.

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Change From Baseline in HbA1c Over Time	The change from Baseline in HbA1c (the concentration of glucose bound to hemoglobin as a percent of the absolute maximum that can be bound) was assessed at Weeks 4, 8, 12, 16 and 20. Least squares means are from an analysis of covariance (ANCOVA) model with treatment and geographic region as fixed effects, and baseline HbA1c as a covariate.	Baseline and Weeks 4, 8, 12, 16, and 20.
Change From Baseline in Fasting Plasma Glucose Over Time	The change from Baseline in fasting plasma glucose was assessed at Weeks 1, 2, 4, 8, 12, 16, 20 and 26. Least Squares Means were from an ANCOVA model with treatment and geographic region as fixed effects, and baseline fasting plasma glucose as a covariate.	Baseline and Weeks 1, 2, 4, 8, 12, 16, 20 and 26.

Collaborators and Investigators

• Sponsor: Takeda
• Investigators: Study Director: Vice President, Clinical Science, Takeda

Publications and helpful links

General Publications

• Pratley RE, Fleck P, Wilson C. Efficacy and safety of initial combination therapy with alogliptin plus metformin versus either as monotherapy in drug-naive patients with type 2 diabetes: a randomized, double-blind, 6-month study. Diabetes Obes Metab. 2014 Jul;16(7):613-21. doi: 10.1111/dom.12258. Epub 2014 Feb 12.

Study record dates

Study Major Dates

• Study Start: November 1, 2009
• Primary Completion (Actual): June 1, 2011
• Study Completion (Actual): June 1, 2011

Study Registration Dates

• First Submitted: December 1, 2009
• First Submitted That Met QC Criteria: December 1, 2009
• First Posted (Estimate): December 2, 2009

Study Record Updates

• Last Update Posted (Estimate): March 26, 2013
• Last Update Submitted That Met QC Criteria: February 17, 2013
• Last Verified: February 1, 2013

More Information

Terms related to this study

• Keywords: Drug Therapy; Hyperglycemia; Type 2 Diabetes mellitus; Hypoglycemia,; Non-insulin dependent diabetes mellitus
• Additional Relevant MeSH Terms: Glucose Metabolism Disorders; Metabolic Diseases; Endocrine System Diseases; Diabetes Mellitus; Diabetes Mellitus, Type 2; Hypoglycemic Agents; Physiological Effects of Drugs; Molecular Mechanisms of Pharmacological Action; Enzyme Inhibitors; Hormones; Hormones, Hormone Substitutes, and Hormone Antagonists; Protease Inhibitors; Incretins; Dipeptidyl-Peptidase IV Inhibitors; Metformin; Alogliptin
• Other Study ID Numbers: SYR-322MET_302; 2009-012652-24 (Registry Identifier: EudraCT); U1111-1112-1912 (Registry Identifier: WHO); DOH-27-0910-3155 (Registry Identifier: SANCTR); CTRI/2010/091/000253 (Registry Identifier: CTRI)